Immune checkpoint inhibitors are a class of drugs that fight with the immune system of the body to fight cancerous cells. However, most patients do not respond to these therapies. There is a newer class of drug that targets two proteins involved in suppressing the body’s immune response against tumors.
Phase I of clinical trials has shown some exciting results, which were conducted in 19 patients suffering from cancer with the molecule M7824. These researchers are also undertaking trials with those suffering from pancreatic cancer and those infected with HPV.
There are many other trials and experiments being taken to treat and cure cancer more effectively in different research institutes. This drug with a dual approach will be a boon in the treatment of cancer, as with a single molecule, multiple therapies are included.
